Physician profile
Maried E Celkis
NPI 1194014365
$1,677.06
in general payments reported to CMS, 2019-2025
16 companies · $529 in 2025
The $529 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $373 · 2024: $774 · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,677.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $516.85 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $228.62 | 2023-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $203.73 | 2023-2024 | Arexvy, Shingrix, Bexsero |
| Otsuka America Pharmaceutical, INC. | $182.08 | 2024-2025 | Rexulti |
| Pfizer INC. | $141.08 | 2024-2025 | |
| Abbvie INC. | $100.22 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $93.63 | 2023-2025 | Airsupra, Breztri, Bevespi Aerosphere |
| Becton, Dickinson and Company | $35.57 | 2025 | Bd Veritor Plus Analyzer |
| Lundbeck LLC | $33.86 | 2024-2025 | Rexulti |
| Amgen INC. | $29.96 | 2024 | Repatha, Otezla |
| Astellas Pharma US INC | $23.14 | 2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $20.16 | 2023 | |
| Exact Sciences Corporation | $19.48 | 2025 | The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $16.78 | 2025 | Capvaxive, Gardasil 9 |
| Vivus LLC | $16.70 | 2024 | Qsymia |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $15.20 | 2024 | Venaseal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maried Celkis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.